UBS analyst Ashwani Verma upgraded Coherus Biosciences to Buy from Neutral with an unchanged price target of $11. The recent selloff in shares presents an attractive entry point as the company’s "topline growth narrative" appears underappreciated at current valuation levels, the analyst tells investors in a research note. Through its multiple biosimilar launches, Coherus has "multiple shots on goal," says the firm. It believes the company’s biosimilar revenue can climb to $580M by 2025 from $211M in 2022.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences management to meet with Truist
- Coherus Biosciences price target raised to $23 from $21 at Mizuho
- Coherus Biosciences management to meet with Mizuho
- Coherus Biosciences price target lowered to $13 from $15 at Barclays
- Coherus Biosciences price target lowered to $26 from $30 at H.C. Wainwright